A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma.
Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a
fixed dose of bortezomib.